{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T22:25:29Z","timestamp":1787869529631,"version":"build-2784847793"},"reference-count":153,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014718","name":"Innovative Research Group Project of the National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82473260"],"award-info":[{"award-number":["82473260"]}],"id":[{"id":"10.13039\/100014718","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>PD-1\/PD-L1 immune checkpoint inhibitors (ICIs) have demonstrated significant clinical efficacy in the treatment of bladder cancer. However, heterogeneous patient responses continue to limit the widespread adoption and overall effectiveness of these therapies. Consequently, identifying strategies to enhance treatment response has become a primary focus of current oncological research. This review summarizes the biological determinants of immune response in bladder cancer, including sex, gut microbiota, molecular subtypes, and the tumor microenvironment (TME). Furthermore, we evaluate key predictive biomarkers for ICI response, such as PD-L1 expression, tumor mutational burden (TMB), and circulating tumor DNA (ctDNA). Synergistic combination strategies\u2014incorporating chemotherapy, radiotherapy, targeted therapy, and nanomedicine\u2014are also detailed to provide novel insights into bladder cancer immunotherapy. Ultimately, the systematic elucidation of immune response mechanisms combined with technological innovation will facilitate the optimization of therapeutic strategies, leading to improved clinical outcomes for patients.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1802404","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T05:23:16Z","timestamp":1776403396000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Research progress in augmentation strategies for PD-1\/PD-L1 inhibitors in bladder cancer: from biological determinants to clinical applications"],"prefix":"10.3389","volume":"17","author":[{"given":"Yaxin","family":"Cheng","sequence":"first","affiliation":[{"name":"Department of Oncology, Third Xiangya Hospital of Central South University","place":["Hunan, Changsha, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenzhi","family":"Deng","sequence":"additional","affiliation":[{"name":"Department of Pathology, Third Xiangya Hospital of Central South University","place":["Hunan, Changsha, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunqing","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Third Xiangya Hospital of Central South University","place":["Hunan, Changsha, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanjun","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Oncology, Third Xiangya Hospital of Central South University","place":["Hunan, Changsha, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Oncology, Third Xiangya Hospital of Central South University","place":["Hunan, Changsha, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)01188-6","article-title":"Current best practice for bladder cancer: a narrative review of diagnostics and treatments","volume":"400","author":"Comp\u00e9rat","year":"2022","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3390\/medsci8010015","article-title":"Epidemiology of bladder cancer","volume":"8","author":"Saginala","year":"2020","journal-title":"Med Sci (Basel)"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.43198","article-title":"Global disparities of cancer and its projected burden in 2050","volume":"7","author":"Bizuayehu","year":"2024","journal-title":"JAMA Netw Open"},{"key":"B4","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s00432-018-2694-5","article-title":"Bladder cancer","volume":"9","author":"Dyrskj\u00f8t","year":"2023","journal-title":"Nat Rev Dis Primers"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2012.04224.x","article-title":"Role of the PD-1 pathway in the immune response","volume":"12","author":"Riella","year":"2012","journal-title":"Am J Transplant"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.102050","article-title":"Avelumab first-line maintenance treatment for advanced urothelial carcinoma: review of evidence to guide clinical practice","volume":"8","author":"Grivas","year":"2023","journal-title":"ESMO Open"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(17)30616-2","article-title":"First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicenter, single-arm, phase 2 study","volume":"18","author":"Balar","year":"2017","journal-title":"Lancet Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2020.02.009","article-title":"Pembrolizumab as first-line therapy in cisplatin-ineligible advanced urothelial cancer (KEYNOTE-052): outcomes in older patients by age and performance status","volume":"3","author":"Grivas","year":"2020","journal-title":"Eur Urol Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(17)30065-7","article-title":"Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicenter, single-arm, phase 2 trial","volume":"18","author":"Sharma","year":"2017","journal-title":"Lancet Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1080\/14796694.2025.2482363","article-title":"Enfortumab vedotin and pembrolizumab: redefining the standard of care for previously untreated advanced urothelial cancer","volume":"21","author":"Sternschuss","year":"2025","journal-title":"Future Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2025.04.019","article-title":"Characterization of patients with lymph node only metastatic urothelial carcinoma treated with nivolumab plus gemcitabine-cisplatin versus gemcitabine-cisplatin alone from the CheckMate 901 trial","volume":"88","author":"Galsky","year":"2025","journal-title":"Eur Urol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06234-x","article-title":"Y chromosome loss in cancer drives growth by evasion of adaptive immunity","volume":"619","author":"Abdel-Hafiz","year":"2023","journal-title":"Nature"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-023-02758-w","article-title":"Bladder cancer, loss of Y chromosome, and new opportunities for immunotherapy","volume":"41","author":"Mankan","year":"2024","journal-title":"Adv Ther"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aav2437","article-title":"Targeting DDR2 enhances tumor response to anti-PD-1 immunotherapy","volume":"5","author":"Tu","year":"2019","journal-title":"Sci Adv"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1101\/2025.08.26.672471","article-title":"Loss of the Y chromosome drives cancer metabolic reprogramming","author":"Subramaniyan","year":"2025","journal-title":"bioRxiv"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01493","article-title":"Naturally-occurring invasive urothelial carcinoma in dogs, a unique model to drive advances in managing muscle invasive bladder cancer in humans","volume":"9","author":"Knapp","year":"2019","journal-title":"Front Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abq2630","article-title":"Androgen conspires with the CD8(+) T cell exhaustion program and contributes to sex bias in cancer","volume":"7","author":"Kwon","year":"2022","journal-title":"Sci Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2022.05.012","article-title":"Androgen receptor-mediated CD8(+) T cell stemness programs drive sex differences in antitumor immunity","volume":"55","author":"Yang","year":"2022","journal-title":"Immunity"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1016\/j.immuni.2022.05.012","article-title":"Androgen receptor-mediated CD8(+) T cell stemness programs drive sex differences in antitumor immunity","volume":"55","author":"Yang","year":"2022","journal-title":"Immunity"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1126\/science.abn3100","article-title":"Hematopoietic loss of Y chromosome leads to cardiac fibrosis and heart failure mortality","volume":"377","author":"Sano","year":"2022","journal-title":"Science"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djz236","article-title":"Why Y? Downregulation of chromosome Y genes potentially contributes to elevated cancer risk","volume":"112","author":"Brown","year":"2020","journal-title":"J Natl Cancer Inst"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/1098-2264(2000)9999:9999<::aid-gcc1034>3.3.co;2-f","article-title":"Karyotypic characterization of urinary bladder transitional cell carcinomas","volume":"29","author":"Fadl-Elmula","year":"2000","journal-title":"Genes Chromosomes Cancer"},{"key":"B23","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1159\/000052252","article-title":"Molecular cytogenetics of bladder cancer progression","volume":"33","author":"Sauter","year":"1998","journal-title":"Eur Urol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.urolonc.2022.04.013","article-title":"Characterizing molecular subtypes of high-risk non-muscle-invasive bladder cancer in African American patients","volume":"40","author":"You","year":"2022","journal-title":"Urol Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.urolonc.2023.11.017","article-title":"Antibiotic use reduces the efficacy of immune checkpoint inhibitors in patients with urothelial carcinoma: a systematic review and meta-analysis","volume":"42","author":"Febriyanto","year":"2024","journal-title":"Urol Oncol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1186\/s12885-025-15094-9","article-title":"Unraveling gut microbiome interferences in cancer immunotherapy: a meta-analysis of diverse drug effects","volume":"25","author":"Xu","year":"2025","journal-title":"BMC Cancer"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1126\/science.abo2296","article-title":"A microbiota-modulated checkpoint directs immunosuppressive intestinal T cells into cancers","volume":"380","author":"Fidelle","year":"2023","journal-title":"Science"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc3421","article-title":"Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy","volume":"369","author":"Mager","year":"2020","journal-title":"Science"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/cnr2.70308","article-title":"Prognostic impact of Clostridium butyricum MIYAIRI (CBM588) in combination with pembrolizumab for advanced urothelial carcinoma: a retrospective cohort study","volume":"8","author":"Arima","year":"2025","journal-title":"Cancer Rep (Hoboken)"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-04189-2","article-title":"Fecal microbiota transplantation plus pembrolizumab and axitinib in metastatic renal cell carcinoma: the randomized phase 2 TACITO trial","author":"Porcari","year":"2026","journal-title":"Nat Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2026.1756107","article-title":"Fecal microbiota transplantation: a novel strategy and challenges in the adjuvant treatment of bladder cancer","volume":"17","author":"Liu","year":"2026","journal-title":"Front Microbiol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.07.036","article-title":"Comprehensive molecular characterization of muscle-invasive bladder cancer","volume":"171","author":"Robertson","year":"2017","journal-title":"Cell"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1318376111","article-title":"Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology","volume":"111","author":"Damrauer","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2014.01.009","article-title":"Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy","volume":"25","author":"Choi","year":"2014","journal-title":"Cancer Cell"},{"key":"B35","doi-asserted-by":"publisher","first-page":"3737","DOI":"10.1038\/s41598-018-22126-x","article-title":"A validation and extended description of the Lund taxonomy for urothelial carcinoma using the TCGA cohort","volume":"8","author":"Marzouka","year":"2018","journal-title":"Sci Rep"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djx243","article-title":"Prognostic power of a tumor differentiation gene signature for bladder urothelial carcinomas","volume":"110","author":"Mo","year":"2018","journal-title":"J Natl Cancer Inst"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicenter, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.cir-15-0274","article-title":"Molecular drivers of the non-T-cell-inflamed tumor microenvironment in urothelial bladder cancer","volume":"4","author":"Sweis","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"B39","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1186\/s12943-023-01897-6","article-title":"The impact of FGFR3 alterations on the tumor microenvironment and the efficacy of immune checkpoint inhibitors in bladder cancer","volume":"22","author":"Komura","year":"2023","journal-title":"Mol Cancer"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-21-2362","article-title":"FGFR3 destabilizes PD-L1 via NEDD4 to control T-cell-mediated bladder cancer immune surveillance","volume":"82","author":"Jing","year":"2022","journal-title":"Cancer Res"},{"key":"B41","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1186\/s12935-021-02314-y","article-title":"Comprehensive analysis of CXCL12 expression reveals the significance of inflammatory fibroblasts in bladder cancer carcinogenesis and progression","volume":"21","author":"Du","year":"2021","journal-title":"Cancer Cell Int"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006643","article-title":"Fibroblast growth factor receptor 3 mutation attenuates response to immune checkpoint blockade in metastatic urothelial carcinoma by driving immunosuppressive microenvironment","volume":"11","author":"Song","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12602","article-title":"FGFR3 alterations in bladder cancer: sensitivity and resistance to targeted therapies","volume":"44","author":"Noeraparast","year":"2024","journal-title":"Cancer Commun (Lond)"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1670574","article-title":"Molecular mechanisms and translational advances in bladder cancer: from driver genes to precision therapy","volume":"15","author":"Xiang","year":"2025","journal-title":"Front Oncol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1158\/2159-8290.cd-14-0863","article-title":"The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints","volume":"5","author":"Llosa","year":"2015","journal-title":"Cancer Discov"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1548234","article-title":"Deciphering T-cell exhaustion in the tumor microenvironment: paving the way for innovative solid tumor therapies","volume":"16","author":"Nair","year":"2025","journal-title":"Front Immunol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-15-1849","article-title":"Reversing T-cell dysfunction and exhaustion in cancer","volume":"22","author":"Zarour","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2016.1249561","article-title":"Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer","volume":"6","author":"Huang","year":"2017","journal-title":"Oncoimmunology"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-032414-112049","article-title":"Coinhibitory pathways in immunotherapy for cancer","volume":"34","author":"Baumeister","year":"2016","journal-title":"Annu Rev Immunol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.cir-15-0151","article-title":"Glioblastoma eradication following immune checkpoint blockade in an orthotopic, immunocompetent model","volume":"4","author":"Reardon","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1111\/iju.70341","article-title":"Translational advances in urothelial carcinoma: from bench to bedside","volume":"33","author":"Iwasawa","year":"2026","journal-title":"Int J Urol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1007\/s12672-025-03000-5","article-title":"Influence of migrasome-associated long noncoding RNAs on the immune microenvironment and prognosis in lung adenocarcinoma","volume":"16","author":"Zhao","year":"2025","journal-title":"Discov Oncol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1038\/s41541-025-01118-9","article-title":"Multi-disciplinary approaches paving the way for clinically effective peptide vaccines for cancer","volume":"10","author":"Shah","year":"2025","journal-title":"NPJ Vaccines"},{"key":"B54","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/s41392-024-01979-x","article-title":"Cold and hot tumors: from molecular mechanisms to targeted therapy","volume":"9","author":"Wu","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-21-0003","article-title":"Low-dose radiotherapy reverses tumor immune desertification and resistance to immunotherapy","volume":"12","author":"Herrera","year":"2022","journal-title":"Cancer Discov"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/nature25501","article-title":"TGFbeta attenuates tumor response to PD-L1 blockade by contributing to exclusion of T cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.170.3.1240","article-title":"Role for IL-10 in suppression mediated by peptide-induced regulatory T cells in vivo","volume":"170","author":"Sundstedt","year":"2003","journal-title":"J Immunol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14102511","article-title":"Single-cell analyses of a novel mouse urothelial carcinoma model reveal a role of tumor-associated macrophages in response to anti-PD-1 therapy","volume":"14","author":"Xu","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/s1471-4906(02)02302-5","article-title":"Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes","volume":"23","author":"Mantovani","year":"2002","journal-title":"Trends Immunol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-019-0127-6","article-title":"Macrophages as regulators of tumor immunity and immunotherapy","volume":"19","author":"DeNardo","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-021-03098-w","article-title":"Infiltration and polarization of tumor-associated macrophages predict prognosis and therapeutic benefit in muscle-invasive bladder cancer","volume":"71","author":"Sun","year":"2022","journal-title":"Cancer Immunol Immunother"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-24-0940","article-title":"Inhibition of JNK signaling overcomes cancer-associated fibroblast-mediated immunosuppression and enhances the efficacy of immunotherapy in bladder cancer","volume":"84","author":"Cui","year":"2024","journal-title":"Cancer Res"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1126\/science.abf9419","article-title":"Tertiary lymphoid structures in cancer","volume":"375","author":"Schumacher","year":"2022","journal-title":"Science"},{"key":"B64","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1038\/s43018-021-00232-6","article-title":"Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression","volume":"2","author":"Schumacher","year":"2021","journal-title":"Nat Cancer"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1914-8","article-title":"Tertiary lymphoid structures improve immunotherapy and survival in melanoma","volume":"577","author":"Cabrita","year":"2020","journal-title":"Nature"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1086-y","article-title":"Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma","volume":"26","author":"Gao","year":"2020","journal-title":"Nat Med"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1085-z","article-title":"Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial","volume":"26","author":"van Dijk","year":"2020","journal-title":"Nat Med"},{"key":"B68","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s12943-021-01428-1","article-title":"Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives","volume":"20","author":"Mao","year":"2021","journal-title":"Mol Cancer"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2024.06.002","article-title":"Adipose tissue remodeling via TSLP-mediated IL-4\/IL-13 signaling: implications for atopic dermatitis and skin barrier","volume":"154","author":"Sugita","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1038\/nri2808","article-title":"The polarization of immune cells in the tumor environment by TGFbeta","volume":"10","author":"Flavell","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00473-5","article-title":"PD-L1 as a biomarker of response to immune-checkpoint inhibitors","volume":"18","author":"Doroshow","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-21-1323","article-title":"JNK signaling promotes bladder cancer immune escape by regulating METTL3-mediated m6A modification of PD-L1 mRNA","volume":"82","author":"Ni","year":"2022","journal-title":"Cancer Res"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1038\/s41418-024-01434-y","article-title":"Methionine-driven YTHDF1 expression facilitates bladder cancer progression by attenuating RIG-I-modulated immune responses and enhancing the eIF5B-PD-L1 axis","volume":"32","author":"Yu","year":"2025","journal-title":"Cell Death Differ"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1172\/jci126022","article-title":"IL-6\/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion","volume":"129","author":"Chan","year":"2019","journal-title":"J Clin Invest"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.3724\/abbs.2024085","article-title":"Posttranslational regulatory mechanism of PD-L1 in cancers and associated opportunities for novel small-molecule therapeutics","volume":"56","author":"Cai","year":"2024","journal-title":"Acta Biochim Biophys Sin (Shanghai)"},{"key":"B76","doi-asserted-by":"publisher","first-page":"4536","DOI":"10.1038\/s41467-021-24769-3","article-title":"NEK2 inhibition triggers anti-pancreatic cancer immunity by targeting PD-L1","volume":"12","author":"Zhang","year":"2021","journal-title":"Nat Commun"},{"key":"B77","doi-asserted-by":"publisher","first-page":"6951","DOI":"10.1038\/s41467-022-34346-x","article-title":"Promoting anti-tumor immunity by targeting TMUB1 to modulate PD-L1 polyubiquitination and glycosylation","volume":"13","author":"Shi","year":"2022","journal-title":"Nat Commun"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1016\/j.xpro.2022.101198","article-title":"An optimized protocol for PD-L1 pathological assessment with patient sample deglycosylation to improve correlation with therapeutic response","volume":"3","author":"Wang","year":"2022","journal-title":"STAR Protoc"},{"key":"B79","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1186\/s12967-024-05502-2","article-title":"N-linked glycosylation of PD-L1\/PD-1: an emerging target for cancer diagnosis and treatment","volume":"22","author":"Duan","year":"2024","journal-title":"J Transl Med"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1021\/acs.analchem.1c03287","article-title":"In situ visualization of PD-L1-specific glycosylation on tissue sections","volume":"93","author":"Huang","year":"2021","journal-title":"Anal Chem"},{"key":"B81","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12929-025-01202-1","article-title":"Post-translational modifications of immune checkpoints: molecular mechanisms, tumor microenvironment remodeling, and therapeutic implications","volume":"33","author":"Hsieh","year":"2026","journal-title":"J BioMed Sci"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-01027-5","article-title":"Regulation of PD-L1 expression in the tumor microenvironment","volume":"14","author":"Yi","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2019.06.008","article-title":"Removal of N-linked glycosylation enhances PD-L1 detection and predicts anti-PD-1\/PD-L1 therapeutic efficacy","volume":"36","author":"Lee","year":"2019","journal-title":"Cancer Cell"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1123244","article-title":"The E3 ubiquitin ligases regulate PD-1\/PD-L1 protein levels in tumor microenvironment to improve immunotherapy","volume":"14","author":"Hou","year":"2023","journal-title":"Front Immunol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(20)30230-0","article-title":"Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicenter, randomized, placebo-controlled phase 3 trial","volume":"395","author":"Galsky","year":"2020","journal-title":"Lancet"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2034442","article-title":"Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma","volume":"384","author":"Bajorin","year":"2021","journal-title":"N Engl J Med"},{"key":"B87","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/s0140-6736(16)32455-2","article-title":"Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicenter, phase 2 trial","volume":"389","author":"Balar","year":"2017","journal-title":"Lancet"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(17)33297-x","article-title":"Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicenter, open-label, phase 3 randomized controlled trial","volume":"391","author":"Powles","year":"2018","journal-title":"Lancet"},{"key":"B89","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","article-title":"Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden","volume":"9","author":"Chalmers","year":"2017","journal-title":"Genome Med"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003087","article-title":"Tumor mutation burden for predicting immune checkpoint blockade response: the more, the better","volume":"10","author":"Zheng","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0792-9","article-title":"Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial","volume":"565","author":"Keskin","year":"2019","journal-title":"Nature"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-024-00932-9","article-title":"Tumor mutational burden: clinical utility, challenges and emerging improvements","volume":"21","author":"Budczies","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2022.40.6_suppl.540","article-title":"Association of tumor mutational burden and PD-L1 with the efficacy of pembrolizumab with or without chemotherapy versus chemotherapy in advanced urothelial carcinoma","volume":"30","author":"Fl\u00e9chon","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-21-3089","article-title":"Putative biomarkers of clinical benefit with pembrolizumab in advanced urothelial cancer: results from the KEYNOTE-045 and KEYNOTE-052 landmark trials","volume":"28","author":"Bellmunt","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-19-4162","article-title":"Nivolumab in patients with advanced platinum-resistant urothelial carcinoma: efficacy, safety, and biomarker analyses with extended follow-up from CheckMate 275","volume":"26","author":"Galsky","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2022.08.022","article-title":"Ancestry-driven recalibration of tumor mutational burden and disparate clinical outcomes in response to immune checkpoint inhibitors","volume":"40","author":"Nassar","year":"2022","journal-title":"Cancer Cell"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-018-0312-8","article-title":"Tumor mutational load predicts survival after immunotherapy across multiple cancer types","volume":"51","author":"Samstein","year":"2019","journal-title":"Nat Genet"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.cir-16-0143","article-title":"Targeted next generation sequencing identifies markers of response to PD-1 blockade","volume":"4","author":"Johnson","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"B99","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/s12916-016-0705-4","article-title":"Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set","volume":"14","author":"Roszik","year":"2016","journal-title":"BMC Med"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1752298","article-title":"Neoadjuvant immunotherapy for lung cancer: current limitations and future prospects","volume":"17","author":"Yang","year":"2026","journal-title":"Front Immunol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2017.7","article-title":"Liquid biopsies come of age: towards implementation of circulating tumor DNA","volume":"17","author":"Wan","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13061448","article-title":"Circulating cell-free DNA in liquid biopsies as potential biomarker for bladder cancer: a systematic review","volume":"13","author":"Herranz","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B103","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13045-022-01351-y","article-title":"Liquid biopsy: current technology and clinical applications","volume":"15","author":"Nikanjam","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1097\/js9.0000000000001372","article-title":"Prognostic significance of circulating tumor DNA in urothelial carcinoma: a systematic review and meta-analysis","volume":"110","author":"Liu","year":"2024","journal-title":"Int J Surg"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2511885","article-title":"ctDNA-guided adjuvant atezolizumab in muscle-invasive bladder cancer","volume":"393","author":"Powles","year":"2025","journal-title":"N Engl J Med"},{"key":"B106","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.annonc.2025.09.139","article-title":"Adjuvant nivolumab versus placebo for high-risk muscle-invasive urothelial carcinoma: 5-year efficacy and ctDNA results from CheckMate 274","volume":"37","author":"Galsky","year":"2026","journal-title":"Ann Oncol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0915-3","article-title":"Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring","volume":"26","author":"Zviran","year":"2020","journal-title":"Nat Med"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-23-1860","article-title":"Circulating tumor DNA analysis in advanced urothelial carcinoma: insights from biological analysis and extended clinical follow-up","volume":"29","author":"Lindskrog","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.12.006","article-title":"Minimal residual disease in colorectal cancer. Tumor-informed versus tumor-agnostic approaches: unraveling the optimal strategy","volume":"36","author":"Mart\u00ednez-Castedo","year":"2025","journal-title":"Ann Oncol"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-18-0143","article-title":"False-positive plasma genotyping due to clonal hematopoiesis","volume":"24","author":"Hu","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13225698","article-title":"Advantages and challenges of using ctDNA NGS to assess the presence of minimal residual disease (MRD) in solid tumors","volume":"13","author":"Larribere","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2024.123000","article-title":"Bacteria-based biohybrids for remodeling adenosine-mediated immunosuppression to boost radiotherapy-triggered antitumor immune response","volume":"316","author":"Wu","year":"2025","journal-title":"Biomaterials"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2025-334861","article-title":"Immunosuppressive contribution of tumor-infiltrating B cells in human intrahepatic cholangiocarcinoma and their role in chemoimmunotherapy outcome","author":"Milardi","year":"2025","journal-title":"Gut"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00766-x","article-title":"Gut microbiota in colorectal cancer development and therapy","volume":"20","author":"Wong","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.cir-15-0064","article-title":"The interplay of immunotherapy and chemotherapy: harnessing potential synergies","volume":"3","author":"Emens","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"B116","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s42003-020-0811-x","article-title":"Combination of chemotherapy and PD-1 blockade induces T cell responses to tumor non-mutated neoantigens","volume":"3","author":"Grimaldi","year":"2020","journal-title":"Commun Biol"},{"key":"B117","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1080\/17425247.2021.1825376","article-title":"Platinum-based chemotherapy in combination with PD-1\/PD-L1 inhibitors: preclinical and clinical studies and mechanism of action","volume":"18","author":"Xue","year":"2021","journal-title":"Expert Opin Drug Delivery"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02100","article-title":"The antitumor activity of combinations of cytotoxic chemotherapy and immune checkpoint inhibitors is model-dependent","volume":"9","author":"Grasselly","year":"2018","journal-title":"Front Immunol"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(21)00152-2","article-title":"Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomized, open-label, phase 3 trial","volume":"22","author":"Powles","year":"2021","journal-title":"Lancet Oncol"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(20)30541-6","article-title":"Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomized, open-label, multicenter, phase 3 trial","volume":"21","author":"Powles","year":"2020","journal-title":"Lancet Oncol"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2309863","article-title":"Nivolumab plus gemcitabine-cisplatin in advanced urothelial carcinoma","volume":"389","author":"van der Heijden","year":"2023","journal-title":"N Engl J Med"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2015.11.024","article-title":"Immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy","volume":"44","author":"Pfirschke","year":"2016","journal-title":"Immunity"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1206682","article-title":"DNA damage checkpoint control in cells exposed to ionizing radiation","volume":"22","author":"Iliakis","year":"2003","journal-title":"Oncogene"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djs629","article-title":"Combining radiotherapy and cancer immunotherapy: a paradigm shift","volume":"105","author":"Formenti","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2016.211","article-title":"Radiotherapy and immunotherapy: a beneficial liaison","volume":"14","author":"Weichselbaum","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2018.04.070","article-title":"Dose-limiting urinary toxicity with pembrolizumab combined with weekly hypofractionated radiation therapy in bladder cancer","volume":"101","author":"Tree","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"key":"B128","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s13046-019-1089-z","article-title":"New combinatorial strategies to improve the PARP inhibitors efficacy in the urothelial bladder cancer treatment","volume":"38","author":"Criscuolo","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1038\/nature10760","article-title":"The DNA damage response and cancer therapy","volume":"481","author":"Lord","year":"2012","journal-title":"Nature"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-16-3215","article-title":"PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression","volume":"23","author":"Jiao","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B131","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1200\/jco.22.00205","article-title":"Durvalumab plus olaparib in previously untreated, platinum-ineligible patients with metastatic urothelial carcinoma: a multicenter, randomized, phase II trial (BAYOU)","volume":"41","author":"Rosenberg","year":"2023","journal-title":"J Clin Oncol"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1200\/jco.19.02044","article-title":"EV-101: a phase I study of single-agent enfortumab vedotin in patients with nectin-4-positive solid tumors, including metastatic urothelial carcinoma","volume":"38","author":"Rosenberg","year":"2020","journal-title":"J Clin Oncol"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N Engl J Med"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-15-1313","article-title":"Enfortumab vedotin antibody-drug conjugate targeting nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models","volume":"76","author":"Challita-Eid","year":"2016","journal-title":"Cancer Res"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3380","article-title":"Immunogenic cell death and DAMPs in cancer therapy","volume":"12","author":"Krysko","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B136","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1200\/jco.22.01643","article-title":"Enfortumab vedotin plus pembrolizumab in previously untreated advanced urothelial cancer","volume":"41","author":"Hoimes","year":"2023","journal-title":"J Clin Oncol"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02887","article-title":"Enfortumab vedotin with or without pembrolizumab in cisplatin-ineligible patients with previously untreated locally advanced or metastatic urothelial cancer","volume":"41","author":"O'Donnell","year":"2023","journal-title":"J Clin Oncol"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-24-1393","article-title":"FDA approval summary: enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma","volume":"30","author":"Brave","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13225724","article-title":"Advances in immunotherapy and the TGF-beta resistance pathway in metastatic bladder cancer","volume":"13","author":"Benjamin","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1021\/acs.accounts.9b00148","article-title":"Combining nanomedicine and immunotherapy","volume":"52","author":"Shi","year":"2019","journal-title":"Acc Chem Res"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202000214","article-title":"Prodrug-based versatile nanomedicine for enhancing cancer immunotherapy by increasing immunogenic cell death","volume":"16","author":"Bai","year":"2020","journal-title":"Small"},{"key":"B143","doi-asserted-by":"publisher","first-page":"4909","DOI":"10.1038\/s41467-020-18626-y","article-title":"Hybrid cellular membrane nanovesicles amplify macrophage immune responses against cancer recurrence and metastasis","volume":"11","author":"Rao","year":"2020","journal-title":"Nat Commun"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.7b00078","article-title":"Enhancing adoptive cell therapy of cancer through targeted delivery of small-molecule immunomodulators to internalizing or noninternalizing receptors","volume":"11","author":"Zheng","year":"2017","journal-title":"ACS Nano"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-02251-3","article-title":"Nanoparticle anchoring targets immune agonists to tumors enabling anti-cancer immunity without systemic toxicity","volume":"9","author":"Zhang","year":"2018","journal-title":"Nat Commun"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aaw6071","article-title":"A bi-adjuvant nanovaccine that potentiates immunogenicity of neoantigen for combination immunotherapy of colorectal cancer","volume":"6","author":"Ni","year":"2020","journal-title":"Sci Adv"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aaw6870","article-title":"Red blood cell-derived nanoerythrosome for antigen delivery with enhanced cancer immunotherapy","volume":"5","author":"Han","year":"2019","journal-title":"Sci Adv"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.1c00448","article-title":"Immunotherapy strategy targeting programmed cell death ligand 1 and CD73 with macrophage-derived mimetic nanovesicles to treat bladder cancer","volume":"18","author":"Zhou","year":"2021","journal-title":"Mol Pharm"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-22-1362","article-title":"Phototherapy with cancer-specific nanoporphyrin potentiates immunotherapy in bladder cancer","volume":"28","author":"Zhu","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.3c04471","article-title":"A cancer nanovaccine for co-delivery of peptide neoantigens and optimized combinations of STING and TLR4 agonists","volume":"18","author":"Baljon","year":"2024","journal-title":"ACS Nano"},{"key":"B151","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1007\/s10238-025-01691-2","article-title":"Oncolytic virotherapy and tumor microenvironment modulation","volume":"25","author":"Rivera-Orellana","year":"2025","journal-title":"Clin Exp Med"},{"key":"B152","doi-asserted-by":"publisher","first-page":"2994","DOI":"10.1002\/1878-0261.12851","article-title":"Targeting immunogenic cell death in cancer","volume":"14","author":"Ahmed","year":"2020","journal-title":"Mol Oncol"},{"key":"B153","doi-asserted-by":"publisher","first-page":"15330338251365700","DOI":"10.37766\/inplasy2025.7.0044","article-title":"Harnessing the gut microbiome in cancer immunotherapy: Mechanisms, challenges, and routes to personalized medicine-a systematic review","volume":"24","author":"Dayhimi","year":"2025","journal-title":"Technol Cancer Res Treat"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1802404\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T05:23:17Z","timestamp":1776403397000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1802404\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,17]]},"references-count":153,"alternative-id":["10.3389\/fimmu.2026.1802404"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1802404","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,17]]},"article-number":"1802404"}}